about
Economic impact of adverse drug events--a retrospective population-based cohort study of 4970 adultsPrevalence, nature and potential preventability of adverse drug events - a population-based medical record study of 4970 adults.Adherence to Antihypertensive Therapy and Elevated Blood Pressure: Should We Consider the Use of Multiple Medications?Earnings and Financial Compensation from Social Security Systems Correlate Strongly with Disability for Multiple Sclerosis PatientsIncome in Multiple Sclerosis Patients with Different Disease Phenotypes.Potentially inappropriate prescribing and adverse drug reactions in the elderly: a population-based study.Cost of illness of patient-reported adverse drug events: a population-based cross-sectional survey.Costs of illness of multiple sclerosis in Sweden: a population-based register study of people of working age.Direct and indirect costs for adverse drug events identified in medical records across care levels, and their distribution among payers.Modelling drug-related morbidity in Sweden using an expert panel of physicians.Comparing Methods for Estimating Direct Costs of Adverse Drug Events.Cognitive function is a major determinant of income among multiple sclerosis patients in Sweden acting independently from physical disability.Effectiveness of person-centred care after acute coronary syndrome in relation to educational level: Subgroup analysis of a two-armed randomised controlled trial.Modelling drug-related morbidity in Sweden using an expert panel of pharmacists'.Comparing costs of illness of multiple sclerosis in three different years: A population-based study.Pharmacoepidemiology at Nordic School of Public Health NHV: Examples from 1999 to 2014.Mighty Mums - a lifestyle intervention at primary care level reduces gestational weight gain in women with obesity.Economic evaluation of a person-centred care intervention in head and neck oncology: results from a randomized controlled trialCohort study of healthcare use, costs and diagnoses from onset to 6 months after discharge for takotsubo syndrome in SwedenClinical relevance of alerts from a decision support system, PHARAO, for drug safety assessment in the older adults.Trajectories of sickness absence and disability pension before and after opioid initiation for noncancer pain: a 10-year population-based studyIncreasing return-to-work among people on sick leave due to common mental disorders: design of a cluster-randomized controlled trial of a problem-solving intervention versus care-as-usual conducted in the Swedish primary health care system (PROSA)Disposable income trajectories of working-aged individuals with diagnosed multiple sclerosisCosts of illness progression for different multiple sclerosis phenotypes: a population-based study in SwedenPerson-Centred Care in Patients with Acute Coronary Syndrome: Cost-Effectiveness Analysis Alongside a Randomised Controlled TrialTransition program for adolescents with congenital heart disease in transition to adulthood: protocol for a mixed-method process evaluation study (the STEPSTONES project)Healthcare, Sickness Absence, and Disability Pension Cost Trajectories in the First 5 Years After Diagnosis with Multiple Sclerosis: A Prospective Register-Based Cohort Study in Sweden
P50
Q28540999-CAD11D6C-1297-42C7-A021-00B19EA16516Q34209590-A6490B4D-4B32-40A5-BD99-3A6CB5C934A2Q35770395-2B7DFEFD-11BF-4796-B866-8C99C53F6B23Q35876028-7A73FBCA-3E37-4355-9806-6FBA1001CF4DQ36247525-BFF35998-F57C-43FE-841F-D7680568A50BQ36275087-5CD0B290-6A37-4540-B279-4D2F352A185FQ36939152-027314B4-A33F-4849-9490-505E1379B05FQ38794935-4FA362EF-8040-4271-AD97-93A47DC46530Q40452958-0296F721-7FE9-47AE-A3E8-4E9A0950320CQ45420124-0C1F9245-047C-4F96-B1FB-8A33713C785EQ47308348-9F3FC22D-D907-4A2D-90BA-94D9D85C5171Q47588069-899DD7E7-9B54-4927-9E97-1C4D7EB97192Q47693108-B23C657B-64E1-4514-9EAC-CD878150554FQ47834552-C498F56C-A703-4136-9B5D-A8FEC98ECD67Q47930580-9BF52B6F-B0B6-423C-BDEF-1BDF01DC1596Q47978824-4A2A17B3-BA8B-4909-B15A-BD0E9774EB57Q55346224-F79ABE74-ECEB-4367-8CA3-0A1ED4523084Q61987022-B5BCF890-184F-4B4E-A8C8-69E6BC2D8400Q64075044-D14897EC-A2B6-4D1E-94AF-3724B39DAC39Q64935266-0E595C4A-D56A-4310-B544-4BCFB848AF9BQ90149310-50703ED3-78B0-4DA8-BB49-03471E96F945Q90318894-40F29D52-72B7-47FF-B865-87B0F7797A87Q90458480-9278574C-00CF-41FE-ADD7-C551326E9FD4Q91725698-B1753D33-9658-49AE-BCE3-A25B2AC83E76Q92065112-678019A1-C66B-4043-A593-A14275649643Q92389731-B98200C2-A24B-41F4-AE78-F8D135423C18Q92675069-CEF34528-56C4-4399-AFC9-59EEB12007F9
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Hanna Gyllensten
@ast
Hanna Gyllensten
@en
Hanna Gyllensten
@es
Hanna Gyllensten
@nl
Hanna Gyllensten
@sl
type
label
Hanna Gyllensten
@ast
Hanna Gyllensten
@en
Hanna Gyllensten
@es
Hanna Gyllensten
@nl
Hanna Gyllensten
@sl
prefLabel
Hanna Gyllensten
@ast
Hanna Gyllensten
@en
Hanna Gyllensten
@es
Hanna Gyllensten
@nl
Hanna Gyllensten
@sl
P1053
H-7378-2016
P106
P21
P31
P3829
P496
0000-0001-6890-5162